Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism

Infection

Volumn 42, Issue 3, 2014, Pages 469-474

  Sukasem, C ^a,c   Manosuthi, W ^b   Koomdee, N ^a,c   Santon, S ^a,c   Jantararoungtong, T ^a,c   Prommas, S ^a,c   Chamnanphol, M ^a,c   Puangpetch, A ^a,c   Sungkanuparph, S ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

CYP2B6; Efavirenz; HIV; Pharmacokinetics; SNP; Subtherapeutic level

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; LAMIVUDINE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CYP2B6 PROTEIN, HUMAN;

ADULT; ADULT DISEASE; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; THAI (PEOPLE); ADOLESCENT; CHEMISTRY; COHORT ANALYSIS; GENETICS; HIV INFECTIONS; PLASMA; SINGLE NUCLEOTIDE POLYMORPHISM; THAILAND; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; CYTOCHROME P-450 CYP2B6; FEMALE; GENE FREQUENCY; HIV INFECTIONS; HUMANS; MALE; PLASMA; POLYMORPHISM, SINGLE NUCLEOTIDE; THAILAND; YOUNG ADULT;

EID: 84901648608     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0560-6     Document Type: Article

References (30)

1. Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. Br J Clin Pharmacol. 2012;74:1005-12.
2. Puthanakit T, Tanpaiboon P, Aurpibul L, Cressey TR, Sirisanthana V. Plasma efavirenz concentrations and the association with CYP2B6-516G[T polymorphism in HIV-infected Thai children. Antivir Ther. 2009;14:315-20.
3. Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003;73:20-30. (Pubitemid 36158483)
4. Sánchez A, Cabrera S, Santos D, Valverde MP, Fuertes A, Domínguez-Gil A, García MJ; Tormes Group. Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrob Agents Chemother. 2011;55:5314-24.
5. Cabrera SE, Santos D, Valverde MP, Domínguez-Gil A, González F, Luna G, García MJ. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother. 2009;53:2791-8.
6. Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, Cavassini M, Fayet A, Décosterd LA, Eap CB, Biollaz J, Telenti A, Csajka C; Swiss HIV Cohort Study. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther. 2009;85:485-94.
7. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-5. (Pubitemid 32055781)
8. Clevenbergh P, Mouly S, Sellier P, Badsi E, Cervoni J, Vincent V, Trout H, Bergmann JF. Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view. Curr HIV Res. 2004;2:309-21. (Pubitemid 39242961)
9. Fabbiani M, Bracciale L, Ragazzoni E, Santangelo R, Cattani P, Di Giambenedetto S, Fadda G, Navarra P, Cauda R, De Luca A. Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure. Infection. 2011;39:563-9.
10. Pretorius E, Klinker H, Rosenkranz B. The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection. Ther Drug Monit. 2011;33:265-74.
11. Gounden V, van Niekerk C, Snyman T, George JA. Presence of the CYP2B6 516G>T polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther. 2010;7:32.
12. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6*6 and*26. Clin Infect Dis. 2007;45:1230-7. (Pubitemid 47580326)
13. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP. Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-400. (Pubitemid 40065906)
14. Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, Supparatpinyo K, Mootsikapun P, Chetchotisakd P, Kiertiburanakul S, Tansuphaswadikul S, Buppanharun W, Manosuthi W, Techasathit W, Ratanasuwan W, Tantisiriwat W, Suwanagool S, Leechawengwongs M, Ruxrungtham K; Thai AIDS Society. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai. 2008;91:1925-35.
15. Sungkanuparph S, Techasathit W, Utaipiboon C, Chasombat S, Bhakeecheep S, Leechawengwongs M, Ruxrungtham K, Phanuphak P; for The Adults and Adolescents Committee of the Thai National HIV Guidelines Working Group. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed. 2010;4:515-28.
16. Chantarangsu S, Cressey TR, Mahasirimongkol S, Capparelli E, Tawon Y, Ngo-Giang-Huong N, Jourdain G, Lallemant M, Chantratita W. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. J Antimicrob Chemother. 2009;64:1265-73.
17. Sukasem C, Churdboonchart V, Chasombat S, Kohreanudom S, Watitpun C, Pasomsub E, Piroj W, Tiensuwan M, Chantratita W. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand. Infection. 2007;35:81-8. (Pubitemid 46536780)
18. Sukasem C, Churdboonchart V, Chasombat S, Kohreanudom S, Watitpun C, Piroj W, Tiensuwan M, Chantratita W. Prevalence of antiretroviral drug resistance in treated HIV-1 infected patients: under the initiative of access to the NNRTI-based regimen in Thailand. J Chemother. 2007;19:528-35. (Pubitemid 350177964)
19. Sukasem C, Churdboonchart V, Sirisidthi K, Riengrojpitak S, Chasombat S, Watitpun C, Piroj W, Tiensuwan M, Chantratita W. Genotypic resistance mutations in treatment-naïve and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: implications for further epidemiologic surveillance. Jpn J Infect Dis. 2007;60:284-9. (Pubitemid 47516874)
20. Sukasem C, Churdboonchart V, Sukeepaisarncharoen W, Piroj W, Inwisai T, Tiensuwan M, Chantratita W. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy. Int J Antimicrob Agents. 2008;31:277-81.
21. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K; N2R Study Team. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis. 2009;48:1752-9.
22. Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix ML, Le Tiec C, Balkan S, Olson D, Olaro C, Pujades-Rodríguez M. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis. 2009;3:81.
23. Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, Puertas G, Taburet AM, Ly N, Rouzioux C, Balkan S, Quillet C, Delfraissy JF. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS. 2007;21:2293-301.
24. van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, de Baar MP, Schuurman R, Burger DM, Zijlstra EE. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005;10:464-70.
25. Carr DF, la Porte CJ, Pirmohamed M, Owen A, Cortes CP. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother. 2010;65:1889-93.
26. Nolan D, Phillips E, Mallal S. Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clin Infect Dis. 2006;42:408-10. (Pubitemid 43122321)
27. Joshi AS, Barrett JS, Fiske WD, Pieniaszek HJ, Ludden TM, Bacheler LT, Ruiz NM. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California, September 1999 [Poster 1201].
28. Pfister M, Labbé L, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, Sheiner LB; Adult AIDS Clinical Trial Group Study 398. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother. 2003;47:130-7. (Pubitemid 36070353)
29. Ståhle L, Moberg L, Svensson JO, Sönnerborg A. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit. 2004;26:267-70.
30. Dahri K, Ensom MH. Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring? Clin Pharmacokinet. 2007;46:109-32. (Pubitemid 46193057)